<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40150">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01819623</url>
  </required_header>
  <id_info>
    <org_study_id>GER-830-13/14-1</org_study_id>
    <nct_id>NCT01819623</nct_id>
  </id_info>
  <brief_title>Effect of Non-pharmacological Therapy on Cognitive Function of Patients With Cognitive Impairment</brief_title>
  <official_title>Effect of Non-pharmacological Therapy on Cognitive Function of Patients With Cognitive Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Medical Sciences and Nutrition, Salvador Zubiran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Medical Sciences and Nutrition, Salvador Zubiran</source>
  <oversight_info>
    <authority>Mexico: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Supervised nonpharmacologic therapy improve cognitive function in patients with Mild
      Cognitive Impairment
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>six months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cognitive function measured by Alzheimer's Disease Assessment Cognitive Scale (ADAS-Cog) sum of boxes after non-pharmacological intervention for six months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognitive function six months after completing intervention</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cognitive function measured by Alzheimer's Disease Assessment Cognitive Scale (ADAS-Cog) six months after completing intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depressive symptoms</measure>
    <time_frame>six months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Depressive symptoms measured by Geriatric Depression Scale (GDS) before and after intervention period</description>
  </secondary_outcome>
  <other_outcome>
    <measure>quality of life</measure>
    <time_frame>six months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Quality of life measured by a scale validated in Spanish before and after intervention period</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">116</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Non-pharmacological therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will be supervised nonpharmacologic therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This group will receive the standard treatment for mild cognitive impairment</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-pharmacological therapy</intervention_name>
    <description>It consists of a weekly two-hour session. During the first hour yoga classes will taught by teacher, during second hour supervised cognitive training by a psychologist based on Memory Program designed by Memory Unit of Madrid</description>
    <arm_group_label>Non-pharmacological therapy</arm_group_label>
    <other_name>Supervised nonpharmacologic therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients 60 years and older with Mild Cognitive Impairment according to Petersen
             Criteria

          -  Phone number available

        Exclusion Criteria:

          -  Untreated depression

          -  Evidence of a reversible cause of cognitive decline

          -  Dementia of any type and stage

          -  Severe sensory deficit unresolved

          -  Metastatic cancer

          -  Hemoglobin level &lt; 8g/dL

          -  Chronic Obstructive Pulmonary Disease Gold stage 3 or 4

          -  Congestive Heart Failure decompensated, unstable angina o Functional Class IV
             according to New York Heart Association

          -  Participation in another protocol that prevents its participation in this research

          -  Chronic use of benzodiazepines, tricyclic antidepressants

          -  Patients whose place of residence can not attend the sessions
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JOSÉ ALBERTO MD ÁVILA, Geriatrician</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Medical Sciences and Nutrition Salvador Zubirán</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ZAIRA MD MEDINA, Neurologist</last_name>
    <phone>525554870900</phone>
    <phone_ext>5701</phone_ext>
    <email>zalome23@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Institue of Medical Sciences and Nutrition Salvador Zubirán</name>
      <address>
        <city>Mexico City</city>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ZAIRA MD MEDINA, NEUROLOGIST</last_name>
      <phone>525554870900</phone>
      <phone_ext>5701</phone_ext>
      <email>zalome23@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>ALBERTO MD MIMENZA, Neurologist</last_name>
      <phone>525554870900</phone>
      <phone_ext>5701</phone_ext>
      <email>ajmaa@prodigy.net.mx</email>
    </contact_backup>
    <investigator>
      <last_name>JOSÉ ALBERTO MD ÁVILA-FUNES, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 22, 2013</lastchanged_date>
  <firstreceived_date>March 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institute of Medical Sciences and Nutrition, Salvador Zubiran</investigator_affiliation>
    <investigator_full_name>José Alberto Ávila Funes</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Mild Cognitive Impairment</keyword>
  <keyword>Cognitive training</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cognition Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
